Clinical Trial Update: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection [Phase 3]

View source ↗

Summary

Phase 3 extension study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• Liposomal Amikacin for Inhalation (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2019-07-26